Roche Battered By Biosimilars But Holds On To Initial Forecast
Still Expects CHF4.6bn Impact From Biosimilar Competition For 2021
Roche insisted that “biosimilar competition is only one factor in the overall picture,” as it reported another set of depleted figures for its three powerhouse biologic brands: Avastin, MabThera/Rituxan and Herceptin.
